Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Invested Capital: 2011-2025

Historic Invested Capital for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $433.5 million.

  • Adma Biologics' Invested Capital rose 86.96% to $433.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $433.5 million, marking a year-over-year increase of 86.96%. This contributed to the annual value of $349.0 million for FY2024, which is 158.14% up from last year.
  • As of Q3 2025, Adma Biologics' Invested Capital stood at $433.5 million, which was up 8.84% from $398.3 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Invested Capital peaked at $433.5 million during Q3 2025, and registered a low of $100.4 million during Q3 2022.
  • Moreover, its 3-year median value for Invested Capital was $188.3 million (2024), whereas its average is $246.1 million.
  • In the last 5 years, Adma Biologics' Invested Capital declined by 11.03% in 2023 and then skyrocketed by 158.14% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Invested Capital stood at $141.2 million in 2021, then rose by 7.65% to $152.0 million in 2022, then dropped by 11.03% to $135.2 million in 2023, then spiked by 158.14% to $349.0 million in 2024, then surged by 86.96% to $433.5 million in 2025.
  • Its Invested Capital was $433.5 million in Q3 2025, compared to $398.3 million in Q2 2025 and $373.4 million in Q1 2025.